USFDA classifies Biocon Biologics Johor Bahru site, Malaysia as VAI
Biocon Biologics remains committed to global standards of quality and compliance
Biocon Biologics remains committed to global standards of quality and compliance
Revenue at Rs 3,623 crore, EBITDA at Rs 718 crore
The US District Court of New Jersey decided to grant a preliminary injunction delaying the launch of LEQSELVI
MNI is dedicated to developing and offering phytochemical (plant-based) products and healthcare solutions, aimed at treating metabolic syndrome
Lilly will license certain baricitinib manufacturing know-how to enable EVA Pharma to manufacture and supply treatment for various immunological diseases
For the 2024 outlook, sales growth is now expected to be 22-28% at CER
EBITDA at Rs. 250 crore, up 47% YoY, with 35% EBITDA margin
The built-in AI-trained algorithms will empower users to proactively intervene when their glucose levels require attention and before a complication can even occur
Renews GMP certifications for India and Malaysia sites
Subscribe To Our Newsletter & Stay Updated